● Single award · contract
Anthim (Obiltoxaximab)
A single federal award, with both ends of the trail linked.
$114.9M
total award value
2024
action date
55 mo
period
75A50324C00006
PIID
Awarding agencyDepartment of Health and Human Services →
RecipientOutside our Phase 1 contractor set: see methodology
Place of performanceNew Jersey →
CategoryNAICS 325412PSC 6505
Competed?Not recorded✓ from source
Total (exact)$114,897,248
More from Department of Health and Human Services
awarded 2024$100.1B
awarded 2023$92B
awarded 2022$80.5B
awarded 2021$80.5B
awarded 2022$71.7B
🔎
Why the labels? The graph is only worth anything if the links are trusted. Facts taken straight from a federal filing are ✓ from source; anything we compute or infer (corporate parents, districts, competitors) is ≈ inferred and worded carefully, never asserted as fact.